BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genelex Corporation Release: Controversial FDA Panel Approves Drug For Use By Children; New DNA Test Alerts Physicians And Parents To Potential Harm


12/7/2006 11:58:00 AM

SEATTLE, Dec. 7 /PRNewswire/ -- An FDA advisory panel's recommendation to allow Celebrex to be marketed for children suffering from juvenile rheumatoid arthritis (JRA) has some experts concerned over long-term health effects.

While the issue of short-term efficacy and safety did not seem a big issue with the FDA panel, long term safety was a matter of concern.

The disease affects some 60,000 children nationally. Celebrex is a member of the COX2 inhibitor class of drugs that include Vioxx and Bextra, both pulled from the market by the FDA because of serious or fatal heart-related injuries or stroke associated with the drug.

According to Howard Coleman, CEO and Founder of Genelex Corporation (Seattle), "thousands of children have an inability to process Celebrex safely. A simple DNA test that tests for the CYP2C9 enzyme alerts parents and physicians that the drug could cause harm to the child." It is estimated that 5 percent of the population has trouble processing Celebrex. If the drug is inadequately processed, it can build to dangerous levels in the bloodstream.

"No medicine that could potentially harm patients should ever be prescribed without knowing how that individual processes the drug. It is time patients and parents responsibly determine how a drug will affect them before it is ever swallowed," continued Coleman.

Adverse drug reactions are responsible for more than 100,000 deaths in the US every year.

Strattera, another drug approved by the FDA for use by children suffering from ADHD, can cause serious damage to the liver -- damage that could be averted.

"Celebrex, Strattera and hundreds of other prescriptions, are potentially very helpful medications," Coleman stated. "Correspondingly, doing appropriate DNA testing in advance would save lives."

Genelex provides consumer-friendly DNA tests that determine whether prescription, over the counter, and herbal remedies are potentially harmful to the patient.

The tests, available to the public without prescription at www.genelex.com , are simple to take. DNA is captured by vigorously rubbing the inside of the cheeks with a swab. The swabs are sent to Genelex for testing. Results are sent directly back to the patient, who may share the results with their physician or pharmacist.

For further information, contact Howard Coleman, President and Founder of Genelex (Seattle), at 206-382-9591.

Genelex Corporation

CONTACT: Genelex Corporation, +1-206-382-9591



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES